Use of the predictive risk model LungFlagTM for lung cancer screening in a Spanish reference center: A cost-effectiveness analysis

María Eugenia Olmedo¹, Luis Gorospe¹, Luis Miguel Seijo², Virginia Pajares³, Mercè Marzo⁴, Joan B. Soriano⁵, Juan Carlos Trujillo³, Natalia Arrabal⁶, Andrés Flores⁶, Fran García⁶, María Crespo⁷, David Carcedo⁷, Carolina Heuser⁸, Olghi Nicolò⁸, Eran Choman⁹, Oliver Higuera¹⁰

¹Hospital Universitario Ramón y Cajal, ²Clínica Universidad de Navarra and Ciberes, ³Hospital Universitario La Princesa, ⁶Roche Farma, ⁷Hygeia Consulting, ⁸Hoffman-la Roche, ⁹Medial EarlySign, ¹⁰ Hospital Universitario La Paz

BACKGROUND


- Several risk prediction models have been developed to select high-risk individuals for lung cancer screening. These allow the calculation of personalized risk as an alternative to standard criteria based on age and cumulative smoking exposure¹.
- LungFlagTM is an artificial intelligence-based risk prediction model effective in the selection of high-risk individuals by evaluating routine clinical and laboratory²⁻³.
- In Spain, there is no national lung cancer screening program, and only a few pilot programs have been developed⁴.
- The aim of this analysis is to assess the cost-effectiveness of LungFlagTM for the identification of high-risk individuals for enrolment in a NSCLC screening programme in a hypothetical Spanish reference center.

METHODS

Model structure

- A joint model combining a decision-tree and a 4-health states Markov model with monthly cycles, was adapted to the Spanish setting (Figure 1).
- The analysis was conducted from the perspective of the Spanish National Health System, so only direct costs were considered.
- A multidisciplinary group of experts validated all parameters and the assumptions made.
- Base case analysis used a 50 years lifetime horizon and a 3% discount rate was applied for both costs and future effects.

Figure 1. Model diagram



- RPM: risk prediction model; TP: True positive; FP: False positive; TN: True negative; FN: False negative.
- The analysis compared the use of LungFlagTM vs no-screening (current situation in Spain).
- Transition probabilities were obtained from the literature and represent the natural history of the disease in the general population⁵.

Target Population

Demographic characteristics were in line with those reported by Gould et al². Two hypothetical cohorts of individuals likely to enter the screening programme of a reference center have been defined: a broader cohort of 5,000 ever-smokers (EvSm) aged 45 years (same as Gould et al² main cohort), and another cohort of 3,000 individuals fitting 2013 USPSTF criteria (aged 55-80 years and 30 pack/years, also used in Gould et al²).

Parameters

- The probability of having cancer was estimated according the 5-year prevalence of the general Spanish population (139.3 per 100,000 inhabitants)⁶, the increased relative risk for being an active smoker or having a smoking history (24.11 for USPSTF cohort and 15 for EvSm cohort)⁷ and the proportion of NSCLC among all lung cancers (82.5%)8.
- Individuals were split across the different cancer stages following the distribution when screening is performed: stages 0-II (75%), stage IIIa (7.5%) and stages IIIb-IV (17.5%) 9-10. Significantly more patients are diagnosed at early stages. In the no-screening arm, individuals entered in the 'undiagnosed NSCLC' health states according to the distribution observed in studies where diagnosis is made symptomatically: stages 0-II (19.1%), stage IIIa (15.8%) and stages IIIb/IV (65.1%)¹¹.
- It was assumed that patient diagnosed with early-stage NSCLC is considered clinically cured if 5 years after treatment they remain disease free.
- An adherence rate to LDCT in the screening program of 56% was considered¹⁰.
- LungFlagTM sensitivity and specificity were obtained from the retrospective case-control study by Gould et al. For 90% specificity, the sensitivity was 44.1%, 42.6% and 32.8% for stages 0-II, stage IIIa and stages IIIb-IV respectively².

Healthcare resources and Costs

Table 2 shows the unit costs (€2,023) of the different healthcare databases and articles¹²⁻¹⁴ .

Table 2. Unit costs used in the model

Healthcare Resources	Unit Cost (€) 35,000.00 111.60	
LungFlag [™] (annual licence)		
LDCT scan		
Primary care visit	25.61	
Specialist visit (e.g: oncologist, pneumologist, etc)	97.14 212.85 284.95 606,93 248.44 238.00	
Emergency visit		
CT scan with contrast		
PET/CT scan		
Bronchoscopy		
Biopsy		
Thoracic surgery	1,443.39	
Radical radiotherapy	4,394.47	
Stereotactic body radiotherapy (SBRT)	6,420.62	
Palliative treatment, stage IIIa (one-off cost)	10,085.89	
Systemic cancer therapy, stages IIIb/IV (one-off cost)	78,642.04	

Sensitivity analyses

Both one-way sensitivity analysis (OWSA) and probabilistic sensitivity analyses (PSA) were carried out to evaluate the uncertainty associated with the model.

RESULTS

 As is shown in table 3, for both cohorts screening using LungFlagTM to identify high-risk individuals provides a higher number of LYs and QALYs and significant savings compared to noscreening, therefore it is a dominant strategy versus the current situation in Spain (no-screening).

Table 3. Results for the case base

	LungFlag™		No-screening		Incremental	
	EvSm (n=5,000)	USPSTF (n=3,000)	EvSm (n=5,000)	USPSTF (n=3,000)	EvSm (n=5,000)	USPSTF (n=3,000)
LYs	112,36	57,010	111,170	56,320	+1,198	+691
QALYs	98,754	48,232	98,125	47,832	+628	+400
Total costs	€11,874,860	€8,779,473	€15,474,573	€11,756,281	€-3,599,713	€-2,976,808
	ICE	dominant	dominant			

- Incremental per patients results showed that the QALYs gain with LungFlagTM was greater in the USPSTF cohort (+0.133) than in the EvSm cohort (+0.126). Also, savings were higher in USPSTF cohort (€-992) compared to EvSm cohort (€-720).
- The OWSA results showed that the dominance of LungFlagTM versus no-screening was maintained for all variables analysed, in both cohorts. Lifetime QALY for stages 0-II, adherence to screening, discount rate for cost and effects, cohort size and LDCT unit costs were the variables that showed the greatest impact (with LungFlag remaining dominant).
- In the PSA, 1,000 simulations were run by second-order Monte Carlo methodology, and 67,2% and 98,6% of the simulations performed showed that LungFlagTM is dominant versus noscreening in EvSm and USPSTF cohorts, respectively.

CONCLUSION

The implementation of LungFlagTM as a risk model for NSCLC screening in a hypothetical Spanish reference center would be cost-effective compared to no-screening for the 2 hypothetical cohorts analyzed, providing savings and a higher clinical benefit. Narrowing the screening to patients who meet USPSTF criteria seems to optimise the benefits of using LungFlagTM

REFERENCES

1. Ten Haaf et al. 2017. PLoS medicine, 14(4). 2. Gould et al. Am J Respir Crit Care Med. 2021;204(4):445–53. 3. Netanel et al. Journal of Thoracic Oncology. 2023. 4. Remon et al. Journal of Thoracic Oncology. 2021. p. 197–204. 5. Hinde et al. Br J Cancer. 2015;113(1):135-41.

6. GLOBOCAN. 5-years prevalence in Spain for Lung Cancer. 2023.

7. Carter et al. New England Journal of Medicine. 2015;372(7):631–40. 8. García-Campelo et al. Clinical and Translational Oncology. 2015;17(12):1020-9.

9. Cervera et al. Arch Bronconeumol. 2022;58(5):406–11.

10. Sanchez-Salcedo. Arch Bronconeumol. 2015;51(4):169-76.

11. Provencio et al. Transl Lung Cancer Res. 2019;8(4):461–75.

12. Gisbert et al. esalud database.2023.

13. De Castro et al. BMC Pulm Med. 2023;23(1).

14. Corral et al. BMC Health Serv Res. 2015;15(1).

